D&D Pharmatech

D&D Pharmatech Granted Fast Track Designation from US FDA for DD01 for the Treatment of NASH/MASH
BioSpace
Tue, 04/2/24 - 11:37 am
D&D Pharmatech
DD01
MASH
NASH
FDA
fast track
D&D bags $137M to fund midphase Alzheimer's, Parkinson's trials
Fierce Biotech
Wed, 08/14/19 - 11:03 am
D&D Pharmatech
neurodegenerative disease
Alzheimer's disease
Parkinson's Disease